Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
1.1Capture by surface thiol reactivity
What ifWhat if a reagent engaged a purified protein by reacting directly with an exposed cysteine?
Claim language“binding a specificity group”
A maleimide-tagged fluorophore reacts with an accessible cysteine on the purified protein at near-neutral pH. Size-exclusion chromatography separates the labeled protein from free fluorophore before fluorescence measurement.
1.2One light activated group
What ifWhat if one photoactive group permanently anchored a bound probe to the target?
Claim language“reacting at least two reactive moieties”
A reversible affinity ligand positions a single diazirine near the surface of a purified protein. Ultraviolet illumination near 365 nm generates a carbene that forms a covalent attachment to a nearby residue.
1.3One exposed target thiol
What ifWhat if the target presented one accessible cysteine for attachment?
Claim language“at least two reactive sites”
A purified model protein presents one solvent-exposed cysteine next to a ligand-binding pocket. A pocket-binding probe positions a maleimide close to that cysteine, where the thiol adds to the maleimide to form a thioether.
1.4Direct attachment to affinity ligand
What ifWhat if each reactive group attached directly to the specificity group?
Claim language“a scaffold disposed between the specificity group”
Two acrylamide groups share direct bonds with solvent-facing positions on an aromatic affinity ligand. The ligand docks in a purified protein pocket and presents the acrylamides to accessible cysteine side chains at the pocket rim.
1.6Paired reversible affinity ligands
What ifWhat if two reversible binding groups held the compound on a protein dimer?
Claim language“at least two reactive moieties”
A flexible polyethylene glycol linker joins two affinity ligands that occupy matching pockets on the dimer. The linker spans the pockets so that when one ligand dissociates, the other keeps it nearby for rebinding.
Section 2 · machine-generated
Variations
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Other field of use
Covalent fixation on sensor surfaces
A glass sensor carries an immobilized synthetic peptide with a terminal adamantyl group and two cysteine side chains. A fluorescent reporter carries a beta-cyclodextrin specificity group and two maleimides on a branched spacer. The beta-cyclodextrin binds the adamantyl group and positions the maleimides near the two cysteines. Each maleimide forms a thioether with a cysteine, and a buffer wash removes unbound reporter before fluorescence measurement.
Component substitution
Coiled coil docking for peptide coupling
A negatively charged coiled-coil peptide serves as the specificity group on a compound with two maleimide arms. The target is a synthetic peptide that presents a complementary positively charged coiled-coil segment followed by a tail with two cysteines. The complementary segments associate in aqueous buffer, positioning the maleimides to form thioethers with the cysteine side chains.
Azide capture with strained alkynes
Two bicyclononyne groups replace thiol-reactive groups on a branched compound bearing a beta-cyclodextrin specificity group. A synthetic target peptide presents a terminal adamantyl group and two azide-bearing side chains at separate positions. Adamantyl binding positions the bicyclononyne groups near the azides, and each pair forms a triazole by strain-promoted cycloaddition in aqueous buffer.
Parameter or scale variation
Spacer length series for dual attachment
Four compounds carry the same beta-cyclodextrin specificity group and two maleimides, with 2, 4, 8, or 12 ethylene glycol units in each arm. Each compound is incubated with a synthetic peptide bearing an adamantyl group and cysteines at positions 3 and 9 for 15, 30, and 60 minutes at pH 7.0 and 25 °C. A thiol-labeling reagent adds a mass tag to each free cysteine after the products are separated from excess compound. Mass spectrometry distinguishes singly attached products with one tag from doubly attached products with zero tags.
Combination with existing systems
Dual capture in a flow cell
A surface plasmon resonance flow cell carries an immobilized synthetic peptide with an adamantyl docking group and two cysteines. The injection system delivers a compound bearing beta-cyclodextrin and two maleimide arms, then holds it in the cell during the coupling interval. Fresh buffer containing soluble adamantane carboxylate competes for the reporter’s beta-cyclodextrin and clears reversibly bound compound. The instrument measures retained surface mass, and a matched channel with cysteine-to-serine substitutions provides a reference.
Automated or data-driven variant
Automated measurement of dual attachment
A liquid handler dispenses a synthetic target peptide bearing an adamantyl group and two cysteines into a microplate, then adds compounds bearing beta-cyclodextrin and two maleimide arms. Software assigns compound concentration and incubation time to each well and schedules acidification to stop coupling. A liquid chromatography system separates the peptide products from free compound, and a second liquid-handling step labels residual cysteines with an isotope-coded thiol reagent. Software integrates the mass-spectral peaks for singly and doubly attached products and reports their relative abundance for each well.
Specific version of a part
Carbohydrate binding in a lectin pocket
A terminal mannose group on the compound docks in the carbohydrate-binding pocket of a purified mannose-binding lectin. The pocket recognizes the arrangement of hydroxyl groups on the mannose ring.
Paired acrylamide reactions with cysteines
Two acrylamide groups on a bound probe face separate cysteine side chains on a purified model protein. Each cysteine thiol adds to its corresponding acrylamide to form a thioether.
Branched lysine scaffold
An amide bond joins the carboxyl group of a lysine scaffold to the affinity ligand. The two lysine amino groups each carry a maleimide-bearing arm.
Binding followed by light activation
A purified protein and a probe carrying an affinity ligand and two diazirines incubate together in buffered solution in the dark. Illumination near 365 nm activates the diazirines, generating carbenes that form covalent bonds with nearby residues.
Section 3 · quoted from USPTO records
Other work
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
1.1(i) binding a specificity group of the chemical compound to a specific target site, and
In particular, in a [c2]daisy chain macromer herein described, the recognition moiety can engage in electrostatic interactions with the secondary amine forming the binding site of a second macromer to properly orient the two macromers for the subsequent interlocking intramacromer covalent bond-forming reaction.
A · US 8,299,276 B2 · ¶ 67
A templated assembly reactant can include a nucleic acid recognition moiety to direct sequence-specific binding to the target template at a position spatially proximate to a corresponding reactant.
B · US 2021/0023227 A1 · ¶ 39
1.2reacting at least two reactive moieties of the chemical compound with respective reactive sites to form one or more covalent bonds,
In some embodiments, two [c2] daisy chain macromers can be interlocked to form a [c2] daisy chain dimer herein described via formation of a covalent bond between the two terminal or internal olefins on each recognition moiety after the two macromers have assembled in solution as directed by the electrostatic interactions between the recognition moieties and binding sites of the partnered macromers.
A · US 8,299,276 B2 · ¶ 149
A templated assembly reactant can also include a selectively-reactive moiety, such that the selectively-reactive moieties of a set of corresponding reactants participate readily in reactions with each other, but may not readily react with other compounds in the pathogenic cell or biological sample.
B · US 2021/0023227 A1 · ¶ 39
1.3wherein the one or more targets comprise the specific target site and at least two reactive sites; and
In some embodiments, two [c2] daisy chain macromers can be interlocked to form a [c2] daisy chain dimer herein described via formation of a covalent bond between the two terminal or internal olefins on each recognition moiety after the two macromers have assembled in solution as directed by the electrostatic interactions between the recognition moieties and binding sites of the partnered macromers.
A · US 8,299,276 B2 · ¶ 149
Templated assembly reactants that come together on a single target template to take part in a templated assembly reaction are referred to herein as a “set of corresponding reactants” or “corresponding templated assembly reactants.” A set of corresponding templated assembly reactants bind in a sequence-specific manner to spatially proximate parts of a nucleic acid target template, and readily react with each other to produce templated assembly ligation products including an ac
B · US 2021/0023227 A1 · ¶
1.4optionally wherein the chemical compound comprises a scaffold disposed between the specificity group and the at least two reactive moieties;
The chemical linker can also be located between the nucleic acid recognition moiety and the selectively-reactive moiety, and/or between the selectively-reactive moiety and the effector partial moiety and/or be a flexible moiety, a cleavage site, and/or a chemical modification site.
B · US 2021/0023227 A1 · ¶ 10
1.5or
1.6(ii) providing the chemical compound to the one or more targets, wherein the chemical compound comprises: a specificity group configured to interact with a specific target site of the one or more targets, and at least two reactive moieties, wherein each of the at least two reactive moieties is configured to react with a respective reactive site of the one or more targets; and
In some embodiments, two [c2] daisy chain macromers can be interlocked to form a [c2] daisy chain dimer herein described via formation of a covalent bond between the two terminal or internal olefins on each recognition moiety after the two macromers have assembled in solution as directed by the electrostatic interactions between the recognition moieties and binding sites of the partnered macromers.
A · US 8,299,276 B2 · ¶ 149
A templated assembly reactant can include a nucleic acid recognition moiety to direct sequence-specific binding to the target template at a position spatially proximate to a corresponding reactant. A templated assembly reactant can also include a selectively-reactive moiety, such that the selectively-reactive moieties of a set of corresponding reactants participate readily in reactions with each other, but may not readily react with other compounds in the pathogenic cell or biological sample.
B · US 2021/0023227 A1 · ¶ 39
1.7incubating the chemical compound with the one or more targets under conditions configured to bind the specificity group to the specific target site and to react the at least two reactive moieties with the respective reactive site to form one or more covalent bonds;
In some embodiments, two [c2] daisy chain macromers can be interlocked to form a [c2] daisy chain dimer herein described via formation of a covalent bond between the two terminal or internal olefins on each recognition moiety after the two macromers have assembled in solution as directed by the electrostatic interactions between the recognition moieties and binding sites of the partnered macromers, in presence of a suitable metathesis catalyst.
A · US 8,299,276 B2 · ¶ 153
Templated assembly ligation product formation is facilitated by the individual templated assembly reactants being assembled in a position- and/or orientation-specific manner through binding interactions, such as hybridization and annealing, with a target nucleic acid.
B · US 2021/0023227 A1 · ¶
1.8or
1.9(iii) providing an effective amount of the chemical compound, wherein the chemical compound comprises a structure having Formula (I);
The methods can include administering a therapeutically effective amount of the targeted templated assembly reactants to the pathogenic cell, and producing at least one active effector structure in the pathogenic cell.
B · US 2021/0023227 A1 · ¶ 6
An empty cell means only that no passage was reproduced there.
Statements in these documents
Possible uses for such molecular actuators include nanoelectromechanical systems and other applications where controlled conformational switches are desirable.
A · US 8,299,276 B2 · ¶ 6
Provided herein are interlocked molecules, that in several embodiments are able to assume extended and contracted conformations which are switchable in a controlled fashion, and related macromers, materials compositions, methods and system.
A · US 8,299,276 B2 · ¶ 7
A method that has emerged to allow delivery of potent interventions to pathogenic cells while mitigating toxicity to normal cells is targeting of therapeutics by directing them against molecular markers specific for pathogenic cells.
B · US 2021/0023227 A1 · ¶ 3
Hence, there exists a need to combat the poor efficacy and/or severe side effects of existing bio-therapeutic interventions.
B · US 2021/0023227 A1 · ¶ 5
Cite aspatent.fyi, US 2026/0355324 A1, claim 1, first published 2026-11-19T10:32:39-05:00, https://patent.fyi/US20260355324/, SHA-256 38b68c3942167714b7f25951445231510f196c38fa2fab01211eb15cadb929a1